Sparks

Roche has entered into a deal to buy US biotech firm 89bio for up to $3.5bn. The deal values 89bio at $14.50 per share plus contingent payments up to $6 per share.

What’s going on here?
The acquisition targets 89bio’s lead drug, pegozafermin, designed to treat metabolic dysfunction-associated steatohepatitis (MASH), a severe liver complication affecting 5–7% of adults globally. Roche will pay $2.4bnupfront, with additional milestone payments potentially bringing the total to $3.5bn. This follows Roche’s expansion into obesity-related treatments, including its $5.3bn Zealand Pharma partnership and $3.1bn Carmot Therapeutics acquisition.

What does this mean?
Roche is strategically positioning itself in the lucrative obesity and metabolic disease market, competing with leaders Eli Lilly and Novo Nordisk. The 89bio acquisition strengthens Roche’s pipeline in cardiovascular, renal and metabolic diseases, while offering combination therapy opportunities with existing programmes. Pegozafermin has the potential to become an effective treatment option for MASH, addressing both inflammation and fibrosis in liver cells. Phase III trial results are expected in 2027–2028.

Why should I care?
For investors, this acquisition demonstrates Roche’s commitment to high-growth therapeutic areas, despite geopolitical challenges. The deal occurs amid heightened US-Switzerland trade tensions, with Switzerland facing 39% tariffs, though pharmaceuticals remain exempt for now. Roche’s willingness to invest up to $3.5bn signals confidence in the obesity and metabolic markets’ long-term prospects and the company’s ability to compete against established players. With MASH affecting millions globally and currently only limited treatment options available, the successful development of pegozafermin could generate substantial returns and establish Roche as a major player in metabolic disease treatment, should subsequent trial data be supportive.